Tetsuro Sasada

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 21

Top Venues

Genes and immunity

Cancer science

Journal for immunotherapy of cancer

International journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Taku Kouro, Naoko Higashijima, Shun Horaguchi, Yasunobu Mano, Rika Kasajima, Huihui Xiang, Yuki Fujimoto, Hiroyuki Kishi, Hiroshi Hamana, Daisuke Hoshino, Hidetomo Himuro, Rieko Matsuura, Shoutaro Tsuji, Kohzoh Imai, Tetsuro Sasada
Novel chimeric antigen receptor-expressing T cells targeting the malignant mesothelioma-specific antigen sialylated HEG1. International journal of cancer 154 (10) (2024)
Shun Horaguchi, Yoshiro Nakahara, Yuka Igarashi, Taku Kouro, Feifei Wei, Kenta Murotani, Seiichi Udagawa, Naoko Higashijima, Norikazu Matsuo, Shuji Murakami, Terufumi Kato, Tetsuro Kondo, Huihui Xiang, Rika Kasajima, Hidetomo Himuro, Kayoko Tsuji, Yasunobu Mano, Mitsuru Komahashi, Yohei Miyagi, Haruhiro Saito, Koichi Azuma, Shuichiro Uehara, Tetsuro Sasada
Prognostic Significance of Plasma Neutrophil Extracellular Trap Levels in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Biomedicines 12 (8) (2024)
Taku Kouro, Naoko Higashijima, Shun Horaguchi, Yasunobu Mano, Rika Kasajima, Huihui Xiang, Yuki Fujimoto, Hiroyuki Kishi, Hiroshi Hamana, Daisuke Hoshino, Hidetomo Himuro, Rieko Matsuura, Shoutaro Tsuji, Kohzoh Imai, Tetsuro Sasada
Novel chimeric antigen receptor-expressing T cells targeting the malignant mesothelioma-specific antigen sialylated HEG1. International journal of cancer 154 (10) (2024)
Shun Horaguchi, Yoshiro Nakahara, Yuka Igarashi, Taku Kouro, Feifei Wei, Kenta Murotani, Seiichi Udagawa, Naoko Higashijima, Norikazu Matsuo, Shuji Murakami, Terufumi Kato, Tetsuro Kondo, Huihui Xiang, Rika Kasajima, Hidetomo Himuro, Kayoko Tsuji, Yasunobu Mano, Mitsuru Komahashi, Yohei Miyagi, Haruhiro Saito, Koichi Azuma, Shuichiro Uehara, Tetsuro Sasada
Prognostic Significance of Plasma Neutrophil Extracellular Trap Levels in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Biomedicines 12 (8) (2024)
Taku Kouro, Naoko Higashijima, Shun Horaguchi, Yasunobu Mano, Rika Kasajima, Huihui Xiang, Yuki Fujimoto, Hiroyuki Kishi, Hiroshi Hamana, Daisuke Hoshino, Hidetomo Himuro, Rieko Matsuura, Shoutaro Tsuji, Kohzoh Imai, Tetsuro Sasada
Novel chimeric antigen receptor-expressing T cells targeting the malignant mesothelioma-specific antigen sialylated HEG1. International journal of cancer (2024)
Feifei Wei, Tetsuro Sasada
Circulating cytokine signatures as a soluble biomarker of immune checkpoint inhibitor therapy in non-small-cell lung cancer. Genes and immunity 25 (1) (2023)
Feifei Wei, Tetsuro Sasada
Circulating cytokine signatures as a soluble biomarker of immune checkpoint inhibitor therapy in non-small-cell lung cancer. Genes and immunity 25 (1) (2023)
Feifei Wei, Tetsuro Sasada
Circulating cytokine signatures as a soluble biomarker of immune checkpoint inhibitor therapy in non-small-cell lung cancer. Genes and immunity 25 (1) (2023)
Feifei Wei, Tetsuro Sasada
Circulating cytokine signatures as a soluble biomarker of immune checkpoint inhibitor therapy in non-small-cell lung cancer. Genes and immunity 25 (1) (2023)
Feifei Wei, Koichi Azuma, Yoshiro Nakahara, Haruhiro Saito, Norikazu Matsuo, Tomoyuki Tagami, Taku Kouro, Yuka Igarashi, Takaaki Tokito, Terufumi Kato, Tetsuro Kondo, Shuji Murakami, Ryo Usui, Hidetomo Himuro, Shun Horaguchi, Kayoko Tsuji, Kenta Murotani, Tatsuma Ban, Tomohiko Tamura, Yohei Miyagi, Tetsuro Sasada
Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures. Journal for immunotherapy of cancer 11 (7) (2023)
Feifei Wei, Tetsuro Sasada
Circulating cytokine signatures as a soluble biomarker of immune checkpoint inhibitor therapy in non-small-cell lung cancer. Genes and immunity (2023)
Koichi Azuma, Huihui Xiang, Tomoyuki Tagami, Rika Kasajima, Yumiko Kato, Sachise Karakawa, Shinya Kikuchi, Akira Imaizumi, Norikazu Matsuo, Hidenobu Ishii, Takaaki Tokito, Akihiko Kawahara, Kenta Murotani, Tetsuro Sasada, Yohei Miyagi, Tomoaki Hoshino
Clinical significance of plasma-free amino acids and tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for developing a prognostic multivariate model. Journal for immunotherapy of cancer 10 (5) (2022)
Mikiya Ishihara, Shigehisa Kitano, Shinichi Kageyama, Yoshihiro Miyahara, Noboru Yamamoto, Hidefumi Kato, Hideyuki Mishima, Hiroyoshi Hattori, Takeru Funakoshi, Takashi Kojima, Tetsuro Sasada, Eiichi Sato, Sachiko Okamoto, Daisuke Tomura, Ikuei Nukaya, Hideto Chono, Junichi Mineno, Muhammad Faris Kairi, Phuong Diem Hoang Nguyen, Yannick Simoni, Alessandra Nardin, Evan Newell, Michael Fehlings, Hiroaki Ikeda, Takashi Watanabe, Hiroshi Shiku
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome. Journal for immunotherapy of cancer 10 (6) (2022)
Taku Kouro, Hidetomo Himuro, Tetsuro Sasada
Exhaustion of CAR T cells: potential causes and solutions. Journal of translational medicine 20 (1) (2022)
Yoshiro Nakahara, Takaji Matsutani, Yuka Igarashi, Norikazu Matsuo, Hidetomo Himuro, Haruhiro Saito, Kouzo Yamada, Kenta Murotani, Tomoaki Hoshino, Koichi Azuma, Tetsuro Sasada
Clinical significance of peripheral TCR and BCR repertoire diversity in EGFR/ALK wild-type NSCLC treated with anti-PD-1 antibody. Cancer immunology, immunotherapy : CII 70 (10) (2021)
Ryosuke Jikuya, Takeshi Kishida, Masahiko Sakaguchi, Tomoyuki Yokose, Masato Yasui, Akihito Hashizume, Tomoyuki Tatenuma, Nobuhiko Mizuno, Kentaro Muraoka, Susumu Umemoto, Masaki Kawai, Mitsuyo Yoshihara, Yoshiyasu Nakamura, Yohei Miyagi, Tetsuro Sasada
Galectin-9 expression as a poor prognostic factor in patients with renal cell carcinoma. Cancer immunology, immunotherapy : CII 69 (10) (2020)
Yasuhiro Shimizu, Toshiaki Yoshikawa, Takashi Kojima, Kayoko Shoda, Kazuto Nosaka, Shoichi Mizuno, Satoshi Wada, Yuki Fujimoto, Tetsuro Sasada, Kenichi Kohashi, Hideaki Bando, Itaru Endo, Tetsuya Nakatsura
Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial. Cancer science 110 (10) (2019)
Takahisa Shirahama, Daisuke Muroya, Satoko Matsueda, Akira Yamada, Shigeki Shichijo, Masayasu Naito, Takuto Yamashita, Shinjiro Sakamoto, Koji Okuda, Kyogo Itoh, Tetsuro Sasada, Shigeru Yutani
A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer. Cancer science 108 (5) (2017)
Shigetaka Suekane, Kousuke Ueda, Kiyoaki Nishihara, Tetsuro Sasada, Takuto Yamashita, Noriko Koga, Shigeru Yutani, Shigeki Shichijo, Kyogo Itoh, Tsukasa Igawa, Masanori Noguchi
Personalized peptide vaccination as second-line treatment for metastatic upper tract urothelial carcinoma. Cancer science 108 (12) (2017)
Shigeru Yutani, Takahisa Shirahama, Daisuke Muroya, Satoko Matsueda, Rin Yamaguchi, Michi Morita, Shigeki Shichijo, Akira Yamada, Tetsuro Sasada, Kyogo Itoh
Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies. Cancer science 108 (9) (2017)
Shinjiro Sakamoto, Satoko Matsueda, Shinzo Takamori, Uhi Toh, Masanori Noguchi, Shigeru Yutani, Akira Yamada, Shigeki Shichijo, Teppei Yamada, Shigetaka Suekane, Kouichiro Kawano, Masayasu Naitou, Tetsuro Sasada, Noboru Hattori, Nobuoki Kohno, Kyogo Itoh
Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11+ or -A33+ allele. Cancer science 108 (4) (2017)

Tetsuro Sasada.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Tetsuro Sasada